It’s a big day for Apricus Biosciences (NASDAQ:APRI). The drug maker announced this morning its execution of a definitive agreement to merge with Seelos Therapeutics, …
Did an iceberg just wallop into Apricus Biosciences (NASDAQ:APRI) stock? The biotech company’s shares are plunging at breakneck speed of almost 15%.
H.C.
The FDA has rejected approval of Apricus’s Vitaros, leaving investors uncertain about the drug’s future.
Apricus Biosciences Inc (NASDAQ:APRI) shares are rising by 3% in Thursday’s trading on the news that Apricus has completed the sale to …
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) shares are trading up 32% in Wednesday’s trading session after announcing an agreement for healthcare giant Eli Lilly (NYSE:LLY) …
Apricus Biosciences Inc (NASDAQ:APRI) investors should be smiling from ear to ear today after the biopharmaceutical company announced that Mexico has granted Apricus` commercialization partner, …
Apricus Biosciences Inc (NASDAQ:APRI) shares are set to slump following the announcement that the drug maker has received feedback in response to its previously …
Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today it released the its Top 20 Biotech …
Roth Capital analyst Scott Henry reiterated a Buy rating on Apricus Biosciences (NASDAQ:APRI) with a $4 price target, following the company’s third quarter results, which were within …
